Although pharmacological inhibition of PI3K suppresses GBM tumor growth and demonstrates favorable outcomes in in-vitro experimental and in-vivo preclinical studies, the clinical data show that their therapeutic effects on GBM patients do not reach the expectations, mostly with stable diseases [40, 42, 62, 103]. This evidence concerns the gene PIK3CA and glioblastoma.